Dr. Antonin (Tony) de Fougerolles has nearly 30 years of experience in drug development and played a key role in the creation of three transformative therapeutic platforms (mRNA, RNAi, single domain antibodies) and built out drug pipelines that have resulted in the approval of numerous medicines in areas such as infectious and inflammatory disease, cardiology, and rare disease. He was previously CEO of Evox Therapeutics, founding CSO of Moderna, CSO of Ablynx, and VP Research at Alnylam Pharmaceuticals.

Tony has received over $80M in grants, raised over $150M in equity financing, authored more than 60 scientific publications, and is an inventor on over 100 issued U.S. patents. He serves as a Board Member to Valerio, and also serves on several other biotech Boards including as Chairman of Helfie AI, Etherna, and Lift Biosciences.

Tony earned his Ph.D. in Immunology from Harvard University.